Wikisage, the free encyclopedia of the second generation, is digital heritage
Belzutifan
Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease.
Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).
Belzutifan is the first drug to be awarded an "innovation passport" by the UK Medicines and Healthcare products Regulatory Agency (MHRA)[1]
ATC
Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs<ref>Dictionary of Medical eponyms/ref>
Interwiki via Wikidata